Based on tests of a representative number of batches of the medicinal product manufactured from December 2020 to April 2024, the presence of N-nitroso-meglumine contamination was confirmed, with a content exceeding the acceptable intake (AI) limit of 100 ng/day. N-nitroso-meglumine is considered a potential carcinogenic impurity. Potential effects: increased carcinogenic risk and harm to patient health.
Download the app and stay informed
Get instant notifications about recalled products and protect your family.
FAQ